- Home
- AVXL vs DEA Comparison
AVXL vs DEA Comparison
Compare AVXL & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- DEA
- Stock Information
- Founded
- AVXL 2004
- DEA 2011
- Country
- AVXL United States
- DEA United States
- Employees
- AVXL N/A
- DEA N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- DEA Real Estate Investment Trusts
- Sector
- AVXL Health Care
- DEA Real Estate
- Exchange
- AVXL Nasdaq
- DEA Nasdaq
- Market Cap
- AVXL 956.7M
- DEA 998.2M
- IPO Year
- AVXL N/A
- DEA 2015
- Fundamental
- Price
- AVXL $8.63
- DEA $21.80
- Analyst Decision
- AVXL Strong Buy
- DEA Buy
- Analyst Count
- AVXL 3
- DEA 6
- Target Price
- AVXL $44.00
- DEA $26.41
- AVG Volume (30 Days)
- AVXL 1.4M
- DEA 455.3K
- Earning Date
- AVXL 08-12-2025
- DEA 10-27-2025
- Dividend Yield
- AVXL N/A
- DEA 8.00%
- EPS Growth
- AVXL N/A
- DEA N/A
- EPS
- AVXL N/A
- DEA 0.38
- Revenue
- AVXL N/A
- DEA $322,861,000.00
- Revenue This Year
- AVXL N/A
- DEA $9.33
- Revenue Next Year
- AVXL N/A
- DEA $6.93
- P/E Ratio
- AVXL N/A
- DEA $59.54
- Revenue Growth
- AVXL N/A
- DEA 7.93
- 52 Week Low
- AVXL $5.22
- DEA $19.33
- 52 Week High
- AVXL $14.44
- DEA $34.95
- Technical
- Relative Strength Index (RSI)
- AVXL 41.62
- DEA 43.19
- Support Level
- AVXL $8.41
- DEA $22.05
- Resistance Level
- AVXL $9.50
- DEA $22.56
- Average True Range (ATR)
- AVXL 0.48
- DEA 0.46
- MACD
- AVXL -0.05
- DEA 0.04
- Stochastic Oscillator
- AVXL 27.98
- DEA 54.43
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.